286 related articles for article (PubMed ID: 22131893)
41. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
42. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
43. Ulcerative colitis: epidemiology, diagnosis, and management.
Feuerstein JD; Cheifetz AS
Mayo Clin Proc; 2014 Nov; 89(11):1553-63. PubMed ID: 25199861
[TBL] [Abstract][Full Text] [Related]
44. Ulcerative colitis: current treatment strategies and future prospects.
Garud S; Peppercorn MA
Therap Adv Gastroenterol; 2009 Mar; 2(2):99-108. PubMed ID: 21180538
[TBL] [Abstract][Full Text] [Related]
45. Medical management of ulcerative colitis.
Rogler G
Dig Dis; 2009; 27(4):542-9. PubMed ID: 19897972
[TBL] [Abstract][Full Text] [Related]
46. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
47. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
48. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
[TBL] [Abstract][Full Text] [Related]
49. [Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation].
Lazebnik LB; Kniazev OV; Konopliannikov AG; Parfenov AI; Ruchkina IN; Mikhaĭlova ZF; Tsaregorodtseva TM; Khomeriki SG; Rogozina VA; Gudkova RB; Shcherbakov PL; Konopliannikova OA
Eksp Klin Gastroenterol; 2010; (11):3-15. PubMed ID: 21485508
[TBL] [Abstract][Full Text] [Related]
50. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.
Fausel R; Afzali A
Ther Clin Risk Manag; 2015; 11():63-73. PubMed ID: 25609972
[TBL] [Abstract][Full Text] [Related]
51. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
Clarke K; Chintanaboina J
Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
[TBL] [Abstract][Full Text] [Related]
52. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
53. Current approaches to the management of new-onset ulcerative colitis.
Marchioni Beery R; Kane S
Clin Exp Gastroenterol; 2014; 7():111-32. PubMed ID: 24872716
[TBL] [Abstract][Full Text] [Related]
54. [A case of refractory pouchitis following surgery for ulcerative colitis successfully treated with adalimumab].
Kato S; Sakakibara Y; Ishihara A; Iwasaki T; Tanaka S; Hasegawa H; Akasaka T; Nakazuru S; Ishida H; Mita E
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(9):732-738. PubMed ID: 31511459
[TBL] [Abstract][Full Text] [Related]
55. Optimal management of steroid-dependent ulcerative colitis.
Khan HM; Mehmood F; Khan N
Clin Exp Gastroenterol; 2015; 8():293-302. PubMed ID: 26648749
[TBL] [Abstract][Full Text] [Related]
56. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK; Wang JJ
Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
[TBL] [Abstract][Full Text] [Related]
57. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
58. Medical therapy of inflammatory bowel disease for the 21st century.
Robinson M
Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
[TBL] [Abstract][Full Text] [Related]
59. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.
Singh S; Proudfoot JA; Dulai PS; Jairath V; Fumery M; Xu R; Feagan BG; Sandborn WJ
Am J Gastroenterol; 2018 Aug; 113(8):1197-1205. PubMed ID: 29925913
[TBL] [Abstract][Full Text] [Related]
60. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
